Lymph Node News and Research

RSS

Lymph is clear or white fluid that travels through vessels, moves within tissues and work to keep all the parts of the body clean. After passing through the channels of the lymphatic system they drain into the lymph nodes. The lymph nodes act as filters along the lymphatic system. These nodes trap germs like bacteria, viruses, toxins as well as cancer cells and ensure that these are removed from the body.

Dartmouth researchers develop unique approach to treat Chronic Lymphocytic Leukemia

Dartmouth researchers have developed a novel and unique approach to treating Chronic Lymphocytic Leukemia (CLL), a form of blood cancer that often requires repeated chemotherapy treatments to which it grows resistant.

17 Mar 2014

Sentinel node biopsy increases survival rates in melanoma patients

Moffitt Cancer Center researchers have been instrumental in making significant improvements to the diagnostic procedure called sentinel node biopsy for melanoma patients and teaching this procedure to physicians from around the world.

10 Mar 2014

Researchers look at health threat to pregnant women with history of Kawasaki disease

In the first study of its type, researchers at the University of California, San Diego School of Medicine have looked at the health threat to pregnant women with a history of Kawasaki disease (KD), concluding that the risks are low with informed management and care.

7 Mar 2014

Perioperative blood transfusion worsens kidney cancer patients’ survival

Patients who receive blood transfusions around the time of their surgery for nonmetastatic renal cell carcinoma have a worse chance of survival than those who do not, results of a large US study suggest.

25 Feb 2014

Avoiding cSMG during radiation therapy is safe in head and neck cancer patients

Avoiding the contralateral submandibular gland during radiation therapy is feasible and safe with advanced stage, node positive head and neck cancers and base of tongue lesions, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.

24 Feb 2014

Reduction of RT to IB lymph nodes may result in better salivary function in head, neck cancer patients

For head and neck cancer patients undergoing radiation therapy, a reduction in the amount of radiation treatment volume to the submandibular (level IB) lymph nodes resulted in better patient-reported salivary function, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.

21 Feb 2014

New approach for delivering vaccines and for stimulating body's immune system to attack tumors

Many vaccines, including those for influenza, polio, and measles, consist of a killed or disabled version of a virus. However, for certain diseases, this type of vaccine is ineffective, or just too risky.

18 Feb 2014

Study affirms new standard for detecting melanoma metastasis to the lymph nodes

Long-term research that was initiated at UCLA's Jonsson Comprehensive Cancer Center on lymphatic mapping and sentinel-node biopsy, techniques for detecting the earliest spread (metastasis) of melanoma, the deadliest form of skin cancer, has confirmed that these techniques significantly prolong patients' disease-free and melanoma-specific survival over the traditional observational "watch and wait" techniques.

14 Feb 2014

Biotheranostics launches complete genomic tests for metastatic cancer patients

bioTheranostics, Inc., today introduced the bioT3 Metastatic Cancer Solution, a suite of genomic-based tests that provide personalized diagnostic information and therapeutic guidance for metastatic cancer patients across the continuum of care.

4 Feb 2014

Primary tumor, node location important in stage III NSCLC prognosis

Researchers from Japan say that classifying clinical mediastinal lymph node status based on the location of the primary tumor and the node involved could improve prognosis in stage III non-small-cell lung cancer compared with pathologic node status.

3 Feb 2014

Navidea Biopharmaceuticals, GMST sign distribution agreement for Lymphoseek Injection in Taiwan

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today it has entered into a distribution agreement for Lymphoseek (technetium Tc 99m tilmanocept) Injection in Taiwan with Global Medical Solutions Taiwan, Ltd., a leading in-country distributor of nuclear medicine and diagnostic imaging products.

7 Jan 2014

Study examines prevalence, severity and factors associated with chronic pain after breast cancer surgery

In a study that included more than 800 women who had undergone surgery for breast cancer, the majority reported some level of pain 12 months after surgery, and factors associated with pain included chronic preoperative pain, chemotherapy, preoperative depression and pain in the area to be operated, according to a study appearing in the January 1 issue of JAMA.

2 Jan 2014

Navidea seeks FDA approval for marketing Lymphoseek Injection for SLN detection

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that it has submitted a Supplemental New Drug Application with the U.S. Food and Drug Administration seeking approval for the marketing and sale of Lymphoseek (technetium 99m tilmanocept) Injection for sentinel lymph node detection in patients with head and neck cancer, an indication for which Lymphoseek was also granted Fast Track designation earlier this month.

17 Dec 2013

Study shows effectiveness of PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay

NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced new results from a combined analysis of the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG-8) and Trans-Arimidex, Tamoxifen, Alone or in Combination (TransATAC) studies. These results, which evaluated samples from 2,137 patients, suggest that the PAM50-based Prosignaz Breast Cancer Prognostic Gene Signature Assay may help identify women with late distant recurrence after five years of endocrine treatment.

13 Dec 2013

Over-use of staging procedures more prevalent in younger, early-stage breast cancer patients

More than one third of younger, early stage breast cancer patients undergo unnecessary imaging procedures - including position emission tomography (PET), computed tomography (CT), nuclear medicine bone scans (NMBS) and tumor markers (TM) -- at the time of staging and diagnosis, according to research from The University of Texas MD Anderson Cancer Center.

13 Dec 2013

New drug combination therapy effective for patients with HER2-positive breast cancer

Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer, regardless of tumor size and whether or not disease has spread to the lymph nodes, according to results from the BETH study presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

11 Dec 2013

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that results from two studies of REVLIMID (lenalidomide) combinations in patients with diffuse large B-cell lymphoma (DLBCL) were presented at the American Society of Hematology annual meeting in New Orleans, La.

11 Dec 2013

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Pharmacyclics, Inc. today announced results of 40 clinical, non-clinical and pre-clinical presentations on ibrutinib (IMBRUVICA™) at the 55TH Annual meeting of the American Society of Hematology (ASH) held in New Orleans, Dec 7 - 10, 2013.

11 Dec 2013

Navidea receives Fast Track designation for Lymphoseek injection

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that the US Food and Drug Administration (FDA) has granted Fast Track designation to Lymphoseek® (technetium 99m tilmanocept) Injection for sentinel lymph node detection in patients with head and neck cancer.

11 Dec 2013

Nanostring Technologies announces nationwide availability of Prosigna Breast Cancer Assay in 2014

NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced nationwide availability of the Prosigna™ Breast Cancer Prognostic Gene Signature Assay beginning in the first quarter of 2014.

From NanoString Technologies 11 Dec 2013

Lymph Node News and Research

Further Reading

Dartmouth researchers develop unique approach to treat Chronic Lymphocytic Leukemia

Sentinel node biopsy increases survival rates in melanoma patients

Researchers look at health threat to pregnant women with history of Kawasaki disease

Perioperative blood transfusion worsens kidney cancer patients’ survival

Avoiding cSMG during radiation therapy is safe in head and neck cancer patients

Reduction of RT to IB lymph nodes may result in better salivary function in head, neck cancer patients

New approach for delivering vaccines and for stimulating body's immune system to attack tumors

Study affirms new standard for detecting melanoma metastasis to the lymph nodes

Biotheranostics launches complete genomic tests for metastatic cancer patients

Primary tumor, node location important in stage III NSCLC prognosis

Navidea Biopharmaceuticals, GMST sign distribution agreement for Lymphoseek Injection in Taiwan

Study examines prevalence, severity and factors associated with chronic pain after breast cancer surgery

Navidea seeks FDA approval for marketing Lymphoseek Injection for SLN detection

Study shows effectiveness of PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay

Over-use of staging procedures more prevalent in younger, early-stage breast cancer patients

New drug combination therapy effective for patients with HER2-positive breast cancer

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Navidea receives Fast Track designation for Lymphoseek injection

Nanostring Technologies announces nationwide availability of Prosigna Breast Cancer Assay in 2014

Immunology eBook

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News